testosterone enanthate has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gilowski, W; Krysiak, R; Okopień, B | 1 |
| Kuwajima, M; Mizuno, A; Murakami, T; Noma, Y; Ogino, T; Sano, T; Shima, K; Zhu, M | 1 |
2 other study(ies) available for testosterone enanthate and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The effect of testosterone on cardiovascular risk factors in men with type 2 diabetes and late-onset hypogonadism treated with metformin or glimepiride.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Hypogonadism; Injections, Intramuscular; Male; Metformin; Middle Aged; Risk Factors; Sulfonylurea Compounds; Testosterone; Treatment Outcome | 2016 |
Ovarian hormone-induced beta-cell hypertrophy contributes to the homeostatic control of beta-cell mass in OLETF female rat, a model of Type II diabetes.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Estradiol; Female; Hypertrophy; Immunity, Innate; Insulin; Islets of Langerhans; Ovariectomy; Ovary; Pancreatectomy; Rats; Rats, Inbred Strains; Sex Characteristics; Testosterone | 1998 |